DEVICE
Aggregometry+Thromboelastography
Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
Platelets Antiaggregation Control Enhancement (PACE) Study
Status
Terminated
Phase
Not applicable
Enrollment
200
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Many patients undergo cardiac surgery without proper suspension of antiaggregation drugs. This is blamed to increase dramatically bleeding and use of allogenic blood transfusions. The investigators test the hypothesis that routine use of aggregometry could show antiaggregated patient and lead to normalization of platelet function via administration of Desmopressin thus limiting bleeding and transfusions.
Interventions
Treatment arms and agents.
DEVICE
Thromboelastography Alone
Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
Timeline
From registration to results.
First posted
Oct 11, 2010
Study start
Dec 2010
Primary completion
Sep 2016
Study completion
Sep 2017
Results posted
Not reported
Registry updated
Jan 26, 2018
Outcomes
What the study measures.
Primary outcomes
Bleeding Volume
Time frame · 12 hours after end of operation
Total amount of bleeding in the first 12 hours after cardiac surgery expressed as milliliters of blood in the chest drains reservoir.
Secondary outcomes
Use of allogenic blood transfusions.
Time frame · In hospital stay (usually 5 to 8 days after operation)
Number of allogenic blood units transfused per patients during the full hospital stay, usually 5 to 8 days after operation.
Eligibility
Who can take part.
- Minimum age
- Not reported
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * all patients undergoing surgical myocardial revascularization. Exclusion Criteria: * none.
Study locations
1 registered sites.
Italy. Showing up to 24 locations stored in the fast local snapshot.
European Hospital
Rome, Italy
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Desmopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
DDAVP for Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.